| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm CEO | XNSE Exchange | INE790G01031 ISIN |
| IN Country | 1,179 Employees | 17 Sep 2025 Last Dividend | 3 Oct 2025 Last Split | - IPO Date |
Shilpa Medicare Limited operates within the pharmaceutical industry, primarily focusing on the production and marketing of a wide range of pharmaceutical products, including active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations. The company caters to diverse markets, spanning across India, the United States, Europe, and other international territories. Founded in 1987, Shilpa Medicare Limited has established itself as a significant player in the pharmaceutical sector, offering both oncology and non-oncology based products. Besides its core pharmaceutical manufacturing services, Shilpa Medicare Limited also extends into contract development and manufacturing, alongside engaging in wind power generation activities. The company is headquartered in Raichur, India, marking its presence with a strong operational base in the region.
Shilpa Medicare Limited produces a broad range of APIs with a strong focus on oncology, including but not limited to capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride. The company also manufactures non-oncology APIs such as ambroxol, tranexmic acid, and ursodeoxycholic acid. These ingredients are crucial for the pharmaceutical industry, serving as the active components in drugs that produce the intended effects.
Shilpa Medicare offers a variety of finished dosage formulations including tablets, capsules, liquid injections, and lyophilized injectables. These products cater to both oncology and non-oncology segments, providing patients with essential medications in various consumable forms.
Part of its expansive portfolio, the company also delves into biologicals, a category comprising products derived from living organisms or contain components of living organisms. Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
Shilpa Medicare extends its expertise to offer contract development and manufacturing services (CDMO), providing comprehensive support from drug development stages to full-scale manufacturing. This service caters to pharmaceutical companies looking to outsource aspects of their R&D and production processes.
The company is engaged in developing novel-drug delivery systems, enhancing the efficacy, safety, and patient experience associated with pharmaceutical products. These innovative delivery systems aim to improve the bioavailability of medications, offering controlled release and targeted delivery options.
Beyond generic offerings, Shilpa Medicare is involved in the manufacture of specialized oncology formulations. These specialized products are tailored to meet specific therapeutic needs in the treatment of cancer, adhering to the highest standards of efficacy and safety.
In addition to its pharmaceutical ventures, Shilpa Medicare Limited engages in renewable energy initiatives, specifically through wind power generation. This diversification represents the company’s commitment to sustainability and its efforts in contributing to the broader energy sector.